Quanterix Corporation Company Analysis & Research
Quanterix is a life sciences company that develops and markets digital immunoassay platforms advancing precision health for life sciences research and diagnostics across North America, Europe, Middle East, Africa, and Asia Pacific regions. The company develops ultra-sensitive detection systems for use in research and in-vitro diagnostics.
The company operates a consumable-based revenue model providing recurring revenue and high margins as the installed base of Simoa instruments grows. The company primarily operates in neurology, oncology, immunology, and inflammation, with focus on selling to academic/governmental research institutions, pharmaceutical, biotechnology, and contract research companies through direct sales and distributors.
Company Overview
Founded: 2007. Headquarters: Billerica, Massachusetts, US. Revenue: $137.4M (2024). Market Cap: $0.22B. Ticker: QTRX (NASDAQ).
Industry
Life Sciences / In-Vitro Diagnostics / Biomarker Detection Technology
Cyborg Score: 6/10 — Solid
Emerging leader in ultra-sensitive biomarker detection with strong revenue growth trajectory, strategic FDA submissions, and expanding clinical applications positioning it for meaningful market impact in precision diagnostics.
Quanterix generated revenue of $137.42 million in 2024, increasing 12.30% year-over-year, with growing strategic momentum in Alzheimer's and biomarker diagnostics. However, losses were -$38.53 million in 2024, 35.9% more than 2023, reflecting continued path to profitability challenges.
Key Strategic Insights for Quanterix Corporation
- Quanterix appointed Everett Cunningham as President and CEO effective January 19, 2026, with company expecting to exceed revenue and cash guidance for full year 2025
- The company announced FDA 510(k) submission for multi-analyte algorithmic blood test for Alzheimer's disease detection in February 2026
- A landmark Nature study revealed Simoa p-Tau 217 assay enabled assessment of 11,000+ samples showing age-related increase in Alzheimer's disease neuropathology prevalence
- Long-standing relationships with leading pharmaceutical companies and research institutions provide stable revenue stream, while collaborations enhance market reach and drive adoption of Simoa technology in new applications
Recent Developments
- (February 2026) FDA 510(k) submission for multi-analyte Alzheimer's disease blood test
- (January 2026) New CEO appointment - Everett Cunningham; exceeded 2025 revenue and cash guidance
- (November 2025) Board and leadership changes; landmark GFAP/NfL blood test study for multiple sclerosis monitoring
- (November 2025) Landmark Nature study on Alzheimer's disease neuropathology published
Competitors & Competitive Landscape
- Roche Diagnostics — Established competitor in immunoassay and molecular diagnostics
- Abbott Diagnostics — Major player in blood screening and diagnostic platforms
- Siemens Healthcare Diagnostics — Large-cap competitor in automated immunoassay systems
According to 3 analysts, the average rating for QTRX is "Hold" with 12-month stock price target of $10.33 representing 35.74% upside from latest price. Quanterix competes in the biomarker diagnostics and ultra-sensitive detection space against established in-vitro diagnostics companies and emerging precision health platforms.
More Company Research
Live Ventures Incorporated Agenus Inc. Everspin Technologies, Inc. Whitefield Industrials Limited Funai Soken Holdings Incorporated United Arab Bank P.J.S.C. GigaCloud Technology Inc. New Hope Corporation Limited Solvay SA American Eagle Outfitters, Inc. Pandora A/S Daifuku Co., Ltd. Edison International Siemens Healthineers AG SeaStar Medical Holding CorporationFull Company Research Reports
Looking for a more in-depth analysis of Quanterix Corporation? AskCyborg's Company Research section contains full AI-generated reports with detailed financials, strategic analysis, and Cyborg Score ratings. Browse the complete company research library or explore industry research reports.
AskCyborg provides AI-powered company research and analysis. Visit AskCyborg for full reports, Cyborg Score ratings, analyst debate audio, and saved-company audio playlists.